VEGFR-3 is predominantly expressed in lymphatic endothelial cells [15], and its inhibition may be involved in known adverse events of selpercatinib, such as peripheral edema [16], chylothorax, and chylous ascites [17]. Here, FLT4 is linked to Chylothorax.